Structural Heart Global Market Size, Share, Trends Analysis, By Product Type, By Procedure, By Indication, By Regional Forecast 2024-2033 | Abbott Laboratories, Comed BV, Medtronic PLC, LivaNova PLC, Biomerics LLC

The Structural Heart Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Structural Heart Market:
https://www.thebusinessresearchcompany.com/report/structural-heart-global-market-report

According to The Business Research Company’s Structural Heart Global Market Report 2024, The structural heart market size has grown strongly in recent years. It will grow from $14.13 billion in 2023 to $15.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increased awareness and screening, supply chain resilience, increasing healthcare expenditure, market concentration, increasing awareness of cardiovascular diseases.

The structural heart market size is expected to see strong growth in the next few years. It will grow to $20.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to demand for heart valve devices, aging population, growing burden of cardiovascular diseases, market segmentation, regional market growth. Major trends in the forecast period include product launches, technological advancements, economic recovery, regulatory impositions, rising incidences of cardiovascular diseases, innovative medical devices.

The rising prevalence of cardiovascular disorders is expected to propel the growth of the structural heart market going forward. Cardiovascular disorders are diseases that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. The rising prevalence of cardiovascular disorders is mostly driven by the aging population, changes in lifestyle and diet, and increasing rates of obesity and diabetes. Structural heart devices and services offer diagnosis and treatment of structural heart anomalies or disorders that affect the valves, chambers, and surrounding tissues using minimally invasive procedures performed rather than open-heart surgery for efficient treatment with lower-risk complications. For instance, in August 2022, according to a report published by the American College of Cardiology, a US-based non-profit medical association, In the United States, it is anticipated that all four cardiovascular risk factors will increase between 2025 and 2060. The largest percentage rise is expected in diabetes, with a 39.3% increase to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Therefore, the rising prevalence of cardiovascular disorders is driving the growth of the structural heart market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12029&type=smp

The structural heart market covered in this report is segmented –
1) By Product: Occluders, Annuloplasty Rings, Heart Valve Balloons, Other Products
2) By Procedure: Heart Valve Stenosis, Heart Valve Regurgitation, Left Atrial Appendage Closure
3) By End Users: Hospitals, Ambulatory Surgical Centers, Cardiac Centers

Technological advancement has emerged as a key trend gaining popularity in the structural heart market. Major market players operating in structural heart are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in February 2023, Eko Health, a US-based digital health company, launched the SENSORA cardiac disease detection platform for non-invasive heart disease detection to primary care. SENSORA features artificial intelligence that objectively identifies structural murmurs, a sign of valvular heart disease, and care pathway analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system by capturing and analyzing heart sounds and electrical signals with its digital stethoscopes. It is intended to aid in key decision-making by detecting care gaps that may be translated into enhanced operational efficiency, such as reduced delays in care delivery, length of stay, and readmission rates, while also enhancing patient and physician satisfaction.

The structural heart market report table of contents includes:
1. Executive Summary